Private Companies in Concord Healthcare Group Co., Ltd. (HKG:2453) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 17% Last Week

Key Insights Significant control over Concord Healthcare Group by private companies implies that the general public has more power to influence management and governance-related decisions 59% of

Simply Wall St03:23 ET

Meichinjiahe (02453) obtained 23.07 million shares of domestic shares pledged by the controlling shareholder Shanghai Medical Star.

Micochip Technology (02453) announced that the company has learned that on July 10, 2024, its controlling shareholder...

Zhitong FinanceJul 10 05:32 ET

Guangzhou Hospital Affiliated to the US and China (02453.HK) was granted 1.3 billion yuan in non-revolving credit

Gelonghui, May 20, 丨 US-China Jiahe (02453.HK) announced that on May 20, 2024, the company's subsidiary Guangzhou Taihe Cancer Hospital Co., Ltd. (“Guangzhou Hospital”) has signed a credit line agreement with the Beijing Branch of Shanghai Pudong Development Bank. Based on this, SPD Bank agreed to grant a non-revolving credit of up to RMB 1.3 billion to Guangzhou Hospital. The withdrawal period of this amount is one year, and the term of a single loan shall not exceed ten years. It is subject to and subject to the terms and conditions of various relevant specific agreements between Guangzhou Hospital and SPD Bank from time to time.

Gelonghui FinanceMay 20 10:11 ET

Concord Healthcare Updates Partnership, Disposal of Interests Terms

Concord Healthcare Group (HKG:2453) logged additional information regarding previously formed partnerships, and the deemed disposals of interests in three of its subsidiaries, according to a filing wi

MT NewswiresMay 15 02:42 ET

Yoshikazu US and China (02453) proposed implementing full circulation of H shares

According to the Zhitong Finance App, the US and China Jiahe (02453) announced that the company submitted an application to the China Securities Regulatory Commission on April 30, 2024 to convert some domestic shares with a face value of RMB 1.00 per share of companies issued abroad to H shares with a face value of RMB 1.00 per share of companies listed on the main board of the Stock Exchange. After obtaining all relevant approvals (including filing and/or approval with the China Securities Regulatory Commission and the Stock Exchange) and complying with all applicable laws, regulations and rules, these domestic shares will be converted to H shares, and the company will apply for listing and trading of these H shares on the main board of the Stock Exchange. On the date of this announcement

Zhitong FinanceApr 30 04:33 ET

Yoshikazu America and China (02453.HK) set up three partnerships with independent third parties to seek long-term strategic development opportunities

Gelonghui, April 26, 丨 US and China Jiahe (02453.HK) announced that in order to promote the company's strategic development and business operation needs, the company and an independent third party set up three partnerships to manage minority shares in the three subsidiaries (i.e. Shanghai Hospital, Shanghai Outpatient Department and Ningbo Jiahe) acquired by the independent third party as a general partner to seek strategic opportunities in line with the company's long-term development. The relevant details are as follows: On April 7, 2024, April 22, 2024, and April 7, 2024, the company and Lingbou Private Equity (independent third party) were established, respectively Joined the partnership Jiaxue Health,

Gelonghui FinanceApr 26 10:32 ET